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Background: There is no consensus on how authors conducting meta-analysis should deal with trial participants with
missing outcome data. The objectives of this study are to assess in Cochrane and non-Cochrane systematic reviews:
(1) which categories of trial participants the systematic review authors consider as having missing participant data
(MPD), (2) how trialists reported on participants with missing outcome data in trials, (3) whether systematic reviewer
authors actually dealt with MPD in their meta-analyses of dichotomous outcomes consistently with their reported
methods, and (4) the impact of different methods of dealing with MPD on pooled effect estimates in meta-analyses
of dichotomous outcomes.
Methods/Design: We will conduct a methodological study of Cochrane and non-Cochrane systematic reviews. Eligible
systematic reviews will include a group-level meta-analysis of a patient-important dichotomous efficacy outcome,
with a statistically significant effect estimate. Teams of two reviewers will determine eligibility and subsequently extract
information from each eligible systematic review in duplicate and independently, using standardized, pre-piloted forms.
The teams will then use a similar process to extract information from the trials included in the meta-analyses of interest.
We will assess first which categories of trial participants the systematic reviewers consider as having MPD. Second,
we will assess how trialists reported on participants with missing outcome data in trials. Third, we will compare what
systematic reviewers report having done, and what they actually did, in dealing with MPD in their meta-analysis. Fourth,
we will conduct imputation studies to assess the effects of different methods of dealing with MPD on the pooled effect
estimates of meta-analyses. We will specifically calculate for each method (1) the percentage of systematic reviews that
lose statistical significance and (2) the mean change of effect estimates across systematic reviews.
Discussion: The impact of different methods of dealing with MPD on pooled effect estimates will help judge the
associated risk of bias in systematic reviews. Our findings will inform recommendations regarding what assumptions for
MPD should be used to test the robustness of meta-analytical results.
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Missing data for the outcomes of interest is a common
problem in randomized trials [1]. In one study, almost one
in every three trials with statistically significant results lost
statistical significance when making plausible assumptions
about the outcomes of participants with missing data
[1]. This reduces our confidence in the effect estimates
resulting not only from these trials but also from
systematic reviews including them.
One challenge with abstracting data from trial reports
is understanding whether or not data from a specific
category of participants is missing. For example, a trial
report might indicate that a certain number of participants
withdrew consent, without indicating whether or not they
continued to be followed-up. In these cases, systematic
review authors might need to make assumptions based on
their best guess.
Moreover, a recent methodological survey found that
systematic reviews are deficient in terms of dealing with
and assessing the risk of bias associated with missing
participant data (MPD) (unpublished data by Akl et al.)
[2]. The Cochrane Collaboration’s Risk of Bias (RoB) tool
was designed to help in assessing bias associated with a
number of factors, including MPD [3]. In a recent study
evaluating stakeholders’ experiences with, and perceptions
of, the Cochrane RoB tool participants cited incomplete
outcome data as one of the most difficult domains to
assess [4]. They also requested more guidance on how
to incorporate RoB assessments into meta-analyses and
conclusions [4].
One approach to assessing the extent of risk of bias
associated with MPD is to conduct sensitivity analyses
based on different assumptions regarding the outcomes of
participants with missing outcome data [5-7]. Examples of
these assumptions include none, and all or a specified
proportion of participants in each group suffering the
outcome of interest. No study has thus far assessed
how systematic reviewers actually deal with MPD. Similarly,
there is a lack of evidence about the impact of different
approaches for dealing with MPD on pooled effect
estimates. This leaves uncertain the extent to which results
of systematic reviews are vulnerable to MPD.
Objectives
The objectives of this study are to assess in Cochrane and
non-Cochrane systematic reviews: (1) which categories of
trial participants the systematic review authors consider as
having MPD, (2) how trialists reported on participants
with missing outcome data in trials, (3) whether system-
atic reviewer authors actually dealt with MPD in their
meta-analyses of dichotomous outcomes consistently with
their reported methods, and (4) the impact of different
methods of dealing with MPD on pooled effect estimates
in meta-analyses of dichotomous outcomes.Methods/Design
We did not register this protocol with PROSPERO given
the register does not accept methodological reviews.
Definitions
MPD refers to outcome data for trial participants that are
not available to the systematic reviewer authors (from the
published trial reports or personal contact with trial
authors) for inclusion in their meta-analyses.
MPD do not relate to any of the following:
 Missing studies (e.g., unpublished studies);
 Entire unreported outcomes (e.g., outcomes planned
in trial protocols but not included in trial reports).
Cochrane systematic reviews are defined as systematic
reviews published in the Cochrane Database of Systematic
Reviews. All other systematic reviews will be considered
non-Cochrane systematic reviews.
A patient-important outcome is defined as an outcome
for which one would answer with “yes” to the following
question: “if the patient knew that this outcome was the
only thing to change with treatment, would the patient
consider receiving this treatment if associated with burden,
side effects, or cost?” We will use a previously developed
hierarchy of outcomes for the selection of one outcome of
interest (Additional file 1) [8]. Categories I, II, and III
include patient-important outcomes. Category IV includes
surrogate outcomes, which are not considered as patient-
important. For a composite outcome to be considered as
patient-important, we will require all of its components to
be patient-important [8].
Categories of participants with potential MPD
We will use the following mutually exclusive categories of
participants that could be potentially counted as having
MPD, at the trial level: “mistakenly randomized and
inappropriately excluded,” “did not receive any treatment,”
“withdrew consent,” “outcome not assessable,” “dead,” “ex-
perienced adverse events,” “non-compliant,” “discontinued
prematurely,” “cross-over,” “moved out of country,” and
“lost to follow-up” (lost to follow-up for reasons not
considered in our other categories). When it is not clear
whether the participants in those categories have MPD or
not, we will assume the following:
 “Mistakenly randomized and inappropriately
excluded,” and “did not receive any treatment”
participant categories, which are defined prior
to the initiation of the trial intervention, most likely
have MPD;
 “Withdrew consent,” “outcome not assessable,” “moved
out of country,” and “lost to follow-up” (for reasons not
considered in our other categories) participant
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trial intervention, most likely have MPD;
 “Dead,” “experienced adverse events,” “non-compliant,”
“discontinued prematurely,” and “cross-over” most
likely do not have MPD.
The number of participants with missing data will be
the sum of the number of participants in each of the
categories of participants known or inferred to have
missing data.
Eligibility criteria
The inclusion criteria for a systematic review:
1. Meets the following minimum criteria we set for a
systematic review of trials:
a. Described as “systematic review” and/or
“meta-analysis” of trials;
b. Compares a clinical intervention to another
(or to no intervention);
c. Reports a search strategy of at least one database;
2. Addresses a preventive or a therapeutic clinical
question in humans (diagnostic, prognostic,
public health, and health service questions are
not eligible);
3. Is either a Cochrane review or a non-Cochrane
review published in one of the core clinical journals;
4. Includes a meta-analysis that meets the following
criteria:
a) Is a group-level meta-analysis of randomized
controlled trials and/or controlled clinical trials
(e.g., network meta-analysis, Bayesian meta-analysis,
and meta-regression are not eligible);
b) Reports an effect estimate expressed as a
dichotomous measure (including relative risk
(RR) or odds ratio (OR); excluding those
produced by generic inverse variance method);
c) Reports a statistically significant pooled effect
estimate from at least two trials for a patient-
important efficacy outcome; statistical significance
refers to p value < 0.05 or confidence interval (CI)
not including 1.0.
The exclusion criteria are:
1. A systematic review that is a duplicate publication
(e.g., a Cochrane systematic review published in
both the Cochrane Library and in a peer-reviewed
journal)
2. A meta-analysis with more than 20 included trials,
for feasibility purposes.
3. A meta-analysis not reporting the numerical data
used or each included trial (i.e., numerator and
denominator per arm).Search strategy
We will search for Cochrane systematic reviews in the
Cochrane Library. We will use the Ovid MEDLINE inter-
face to search for non-Cochrane systematic reviews in the
Core Clinical Journals (119 English language clinical jour-
nals indexed under Abridged Index Medicus by the
National Library of Medicine (available at http://www.
nlm.nih.gov/bsd/aim.html). The Abridged Index Medicus
was initiated in 1970 to enable direct access to selected
biomedical journals of interest to practicing physicians.
We will restrict the search to 1 year but will not impose
any language restrictions. Additional file 2 provides the
details of the search strategy.
Random sampling of citations
We will retrieve two random samples of Cochrane and
non-Cochrane systematic reviews from the pool of cita-
tions identified by our search. We will screen these two
samples for eligibility using the above criteria. We will
repeat the random sampling process as needed until
reaching the final sample size, which will include the
same number of Cochrane and non-Cochrane systematic
reviews (see Sample size section).
Selection process
We will conduct title and abstract screening, full-text
screening, and data abstraction in teams of two reviewers
working independently and in duplicate. At the title and
abstract screening stage, we will obtain the full text for
any citation included by at least one reviewer. At the full-
text screening and data abstraction stages, the reviewers
will resolve discrepancies by consensus, and if unsuccess-
ful, with the help of a third reviewer. We will carry out
calibration exercises at each level of the process for the
purpose of verifying the validity and consistency of the
review process. We will also develop and pilot test stan-
dardized data abstraction forms with instructions. A core
group will communicate regularly to discuss progress and
potential difficulties. A study flow will be developed to
describe the results of the different steps of the selection
process.
If a systematic review reports on more than one pair-
wise comparison with eligible meta-analyses, we will
select the first one reported in the main text. If the
selected comparison includes more than one eligible
meta-analysis, we will select the one with the outcome that
ranks the highest on the outcome hierarchy (Additional
file 1). If more than one outcome ranks the same on the
outcome hierarchy, we will select the one reported first in
the main text.
Data abstraction
We will conduct data abstraction using web-based system-
atic review software (DistillerSR™). In a first phase, we will
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eligible meta-analyses. In the second phase, we will collect
data from trials included in the eligible meta-analyses.
Phase 1: we will abstract the following data from each
eligible systematic review:
Characteristics of the systematic review:
 Type of systematic review (i.e., Cochrane vs.
non-Cochrane);
 Use or non-use of the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE)
approach for assessing the confidence in effect
estimates by outcome; [9]
 Source of funding (e.g., private for profit, private not
for profit, governmental, not funded, not reported).
Characteristics of the comparison of interest:
 Type of intervention and control (e.g.,
pharmacological, surgical);
 Outcome ranking on patient-importance hierarchy
(i.e., I, II, III);
 Duration of follow-up for outcome measurement;
 Type of outcome (e.g., efficacy, safety).
Missing participant data:
In reference to the comparison and outcome addressed
in the eligible meta-analysis, we will verify whether the
systematic review:
 Documented the categories of participants that
could potentially be counted as having MPD
(see previous section “Categories of participants
with potential MPD”), and when documented, the
number within each category;
 Reported number of MPD and at what level (e.g., at
the study arm level, study level, across studies);
 Explicitly stated using the following for their
meta-analysis: intention-to-treat, modified
intention-to-treat, per protocol, or as treated;
 Explicitly stated analyzing participants in the group
to which they were randomized;
 Explicitly stated the analytical method for dealing
with MPD in the eligible meta-analysis (i.e., to
account for MPD when generating the best effectTable 1 Numerical information from each trial to be used in t
Intervention arm
Number of
participants
randomized
Number of
participant with
missing data
Number of trial participants a b
The number of participants with missing data is the sum of the number of participa
missing data (see section “Categories of participants with potential MPD”).estimate): complete case analysis, making assumptions
for MPD, using the assumption used by the trialists,
or excluding trials with high rate of MPD. Tables 1
and 2 present the numerical details of the different
assumptions that could be used to deal with MPD;
 Explicitly stated any additional meta-analyses for
dealing with MPD for the outcome of interest
(“reported analytical method”) (i.e., to judge the
risk of bias associated with MPD): complete case
analysis, making assumptions for MPD, using the
assumption used by the trialists, or excluding trials
with high rate of MPD (see Tables 1 and 2);
 Explicitly stated using assumptions for MPD accounted
for uncertainty associated with imputing events;
 Justification for the analytical method used to deal
with MPD in the eligible meta-analysis;
 Tool(s) used to judge risk of bias associated with
MPD at the study level (e.g., Cochrane RoB tool),
if any;
 Method(s) used to assess risk of bias associated
with MPD at the meta-analysis level (e.g., sensitivity
analysis, subgroup analysis), if any.
Data from the eligible meta-analysis:
 Number of trials included;
 Numerator and denominator used in the meta-analysis
for each arm for each trial;
 Number of MPD reported (per arm or combined);
 Pooled relative effect measure (RR or OR) and its
associated CI, p value, and measure of heterogeneity
(I2);
 Analysis model used (i.e., random effect or fixed effect);
 Statistical method used (e.g., Mantel-Haenszel or Peto);
 Results of sensitivity analyses applied to account
for MPD.
Phase 2: we will abstract the following data from all
trials included in each eligible meta-analysis:
Characteristics of the trials:
 Type of reference (e.g., abstract, full-text article);
 Type of trial (e.g., randomized controlled trial,
controlled clinical trial);
 Duration of follow-up for outcome measurement;he imputation analyses
Control arm
Number of
observed
events
Number of
participants
randomized
Number of
participant with
missing data
Number of
observed
events
c e f g
nts in each of the categories of participants known or assumed to have
Table 2 Numerical details of different methods to be used in the imputation analyses
Analytic method Intervention arm Control arm
Numerator Denominator Numerator Denominator
Complete (available) case analysis c a − b g e − f
None has event c a g e
All had event b + c a f + g e
Best case scenario c a f + g e
Worst case scenario b + c a g e
Using the concept of RILTFU/FU [b x y x c/(a − b)] + c a [f x z x g/(e − f)] + g e
Incidence for missing participants same as
observed in same arma
[b x c/(a − b)] + c a [f x g/(e − f)] + g e
Incidence for missing participants in both
arms same as observed in control arm
[b x g/(e − f)] + c a [f x g/(e − f) ] + g e
Refer to Table 1 for what values letters a-g refer to y and z refer to RILTFU/FU in the intervention and control arm, respectively [8].
aThis is a special case of RILTFU/FU method where y = z = 1.
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for profit, governmental, not funded, not reported);
 Type of outcome (e.g., efficacy, safety).
Missing participant data:
 Presence of MPD;
 Whether the trialists report the MPD for this
specific outcome, as opposed to reporting premature
end of follow-up for trial participants in general;
 Whether the trialists followed-up categories of
participants that could be potentially counted as
having MPD (see previous section “Categories of
participants with potential MPD”);
 Whether the trialists included in the analysis the
categories of participants that could be potentially
counted as having MPD in the analysis;
 Level of reporting number of participants with MPD
(e.g., per arm, both arms combined);
 Whether the trialists described the pattern of
missingness;
 Whether the trialists compared the baseline
characteristics of participants with and without
MPD (e.g., MPD group vs. non-MPD group, MPD
first arm vs. MPD second arm)
 Number of participants in each of the categories
of participants that, following our rules stated
previously, would be counted as having MPD,
per arm;
 Whether the trialists report using the following
for their analysis: intention-to-treat, modified
intention-to-treat, per protocol, or as treated;
 Whether the trialists report analyzing participants in
the group to which they were randomized;
 Whether the trialists report the analytical method
for dealing with MPD in the main analysis, i.e., to
account for MPD when generating the effectestimate (e.g., complete case analysis, making
assumptions for MPD);
 Whether methods using assumptions for MPD
accounted for uncertainty associated with imputing
events;
 Whether the trialists provided any justification for
the method used to deal with MPD in the main
analysis;
 Method(s) used to assess risk of bias associated with
MPD in the analysis (e.g., sensitivity analysis,
different methods for different subgroups of
participants with MPD), if any;
 Numerical information for the comparison and
outcome of interest: number randomized per arm,
number of observed events per arm (see Table 1);
 Relative effect measure (e.g., RR, OR) and its
associated CI, and p value;
 Analytical method “actually” used by the systematic
review authors based on the numerical information
provided by the trialists;
 Whether the trialists report any additional analytical
methods for dealing with MPD (“reported analytical
method”), i.e., to judge the risk of bias associated
with MPD (e.g., complete case analysis, making
assumptions for MPD);
 Whether the trialists incorporated implications of
MPD in results or discussion sections.
Sample size
The sample size will be based on the goal of achieving
enough precision (CI width of 0.1) around the proportion
of systematic reviews (both Cochrane and non-Cochrane)
for which the pooled effect estimate crosses the boundary
of conventional statistical significance (further details
below under “Impact of different methods of dealing with
MPD on pooled effect estimates”). We will use the find-
ings after including the first 100 systematic reviews to
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bers of Cochrane and non-Cochrane systematic reviews.
Data analysis
Agreement
We will assess agreement between reviewers for inclusion
of systematic reviews at the full-text screening stage for
their first judgment (i.e., before the step of reaching agree-
ment by consensus) using chance-corrected agreement
(kappa statistic). If fewer than 15% or more than 85% of
citations are included in this study, we will measure agree-
ment using chance-independent agreement (phi statistic)
[10]. We will interpret the agreement statistics using the
guidelines proposed by Landis and Koch [11]: kappa
values of 0 to 0.20 represent slight agreement, 0.21 to 0.40
fair agreement, 0.41 to 0.60 moderate agreement, 0.61 to
0.80 substantial agreement, and greater than 0.80 almost
perfect agreement. We will use these same thresholds for
interpreting phi.
Characteristics of the included systematic reviews
We will conduct a descriptive analysis of the characteristics
of included systematic reviews and the comparisons of
interest. For all descriptive analyses, we will use percentages
for dichotomous variables. To describe the distribution of
continuous variables, we will use the mean and standard
deviation when distribution is near normal and median and
interquartile range (IQR) when the distribution is substan-
tially skewed. We will use the Shapiro-Wilk test to evaluate
whether the distributions of continuous variables violate
assumptions of normality.
For all relevant analyses, we will test for the statistical
significance of the differences between the Cochrane and
non-Cochrane reviews. For dichotomous variables, we will
use the chi-square test. For continuous variables, we will
use Student’s two independent sample t-test for two inde-
pendent samples when the distribution is normal and the
Mann–Whitney U-test (a non-parametric test for two inde-
pendent samples) when the distribution is not normal.
When results differ, we will present the results stratified
by the systematic review type (i.e., Cochrane vs. non-
Cochrane) and consider presenting the overall results as
well. When results do not differ, we will focus on the overall
results but consider presentation of stratified results as well.
Categories of trial participants reviewers considered as
having MPD
For each category of participants that could be poten-
tially counted as having MPD (refer to section above on
“Categories of participants with potential MPD”), we will
calculate:
 The percentage of systematic reviews documenting
that category; The percentage of trials documenting that category;
 The distribution across trials of the proportion of
participants belonging to that category.
We will compare (1) data from the trial regarding the
number of participants in the different categories of par-
ticipants that, following our rules stated previously, would
be counted as having MPD, to (2) the number of partici-
pants considered in the systematic review as having MPD.
We will conduct this analysis irrespective of what categor-
ies of participants that could be potentially counted as
having MPD are reported by the systematic review.
Reporting of MPD by trialists
We will conduct a descriptive analysis of the reporting
of MPD by trialists. We will calculate:
 The percentage of trials following-up categories of
participants that could be potentially counted as
having MPD;
 The percentage of trials documenting the number of
participants in each arm with MPD; if applicable;
 The percentage of trials documenting different
numbers of participants with MPD across different
outcomes, if applicable;
 The percentage of trials documenting the pattern of
missingness;
 The percentage of trials documenting the comparison
of the baseline characteristics of participants with and
without missing participant data;
 The percentage of trials documenting the methods
used to assess risk of bias associated with MPD in
the analysis.
Reported vs. actual method of dealing with of MPD in
meta-analysis
First, we will conduct the following descriptive analysis:
 The percentage of systematic reviews using each of
the terms “intention-to-treat,” “modified intention-
to-treat,” “per protocol,” and “as treated;”
 The percentage of systematic reviews reporting a
plan to analyze participants in the group to which
they were randomized;
 The percentage of systematic reviews using different
analytical methods for dealing with MPD in the
main analysis, i.e., when generating the best effect
estimate;
 The percentage of systematic reviews using imputed
data for MPD and accounting for uncertainty
associated with imputing events;
 The percentage of systematic reviews justifying the
analytical method used to deal with MPD in the
eligible meta-analysis;
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analytical methods (e.g., sensitivity analysis, subgroup
analysis) to judge risk of bias associated with MPD;
 The percentage of systematic reviews using different
tools (e.g., Cochrane RoB tool) to measure risk of
bias associated with MPD in individual trials, and
for the body of evidence, across trials, supporting
the outcome of interest.
Second, we will analyze the “actually used analytical
method” for dealing with MPD. For this purpose, and
for each trial included in the eligible meta-analysis, we
will compare data from the trial report (number random-
ized, number of observed events, number with missing
data) to the corresponding data included in the meta-
analysis (numerator, denominator). Based on these com-
parisons, we will categorize the “actually used analytical
method” for dealing with MPD as: complete case analysis,
making assumptions for MPD, using the assumption used
by the trialists, or excluding trials with high rate of MPD.
We will develop and pilot test specific rules for cat-
egorizing the “actually used analytical method” for deal-
ing with MPD. As part of this process, we will note
when some of these data appear to have been wrongly
abstracted. Two reviewers will make these judgments in
duplicate and independently. They will resolve discrep-
ancies by consensus, and if unsuccessful, with the help
of a third reviewer.
Third, we will conduct a bivariate analysis to assess
the association between the “actually used analytical
method” and the following characteristics:
 Whether the trialists report using the following for
their analysis: intention-to-treat, modified intention-
to-treat, per protocol, as treated;
 Whether the trialists report analyzing participants in
the group to which they were randomized.
Fourth, we will compare the “actually used analytical
method” for dealing with MPD with the “reported analyt-
ical method.” The latter refers to the method the authors
report for dealing with MDP (e.g., complete case analysis,
making assumptions for MPD, using the assumption used
by the trialists, or excluding trials with high rate of MPD).
We will calculate the percentage of systematic reviews
with “discrepancy” between “reported” and “actually used”
analytical methods. We will display the results in a matrix
with “reported” analytical methods displayed in columns
and “actually used” analytical methods displayed in rows.
We will test whether the distribution of studies according
to these two variables is due to chance using the chi-
square statistical test.
Finally, we will conduct a multivariable logistic regres-
sion analysis using the “discrepancy” as the dependentvariable and the general characteristics of the included
systematic reviews as the independent variables: type of
systematic review (i.e., Cochrane vs. non-Cochrane), use
of GRADE, source of funding, type of intervention, and
outcome patient-importance ranking.
Impact of different methods of dealing with MPD on pooled
effect estimates
For the following analyses, we will use “original effect esti-
mate” to refer to the effect estimate reported in the eligible
meta-analyses. For each eligible meta-analysis, we will first
attempt to reproduce the original analysis. When this
analysis generates a different effect estimate that is not
statistically significant, we will exclude the corresponding
meta-analysis from this part of the study.
Then, we will apply a number of methods of dealing
with MPD (see below). Each of these methods will gener-
ate a set of values for the numerator and denominator in
each arm of each trial included in the meta-analysis. We
will use these values to conduct the sensitivity analyses
using the same pooled relative effect measure (RR or OR),
the same analysis model (random effect or fixed effect),
and the same statistical method (e.g., Mantel-Haenszel,
Peto) used by the systematic review authors to generate
the original effect estimate. We will use the “assumption
pooled effect estimates” to refer to the results of those
sensitivity analyses. For outcomes that have a measure of
effect greater than 1.00, we will reverse the direction of
the comparison at the time of the analysis.
In terms of applying different methods of dealing with
MPD, we will start by conducting a complete case analysis.
As described in detail in the subsequent paragraphs, we
will also apply both “implausible” (but sometimes used)
and more plausible assumptions for dealing with MPD.
We will apply to each of these assumptions and statistical
approaches to take uncertainty into account.
We will use the following implausible assumptions, [5]
described in more details in Table 2:
 None of the participants with MPD had the event;
 All participants with MPD had the event;
 None of the participants with MPD in the treatment
group had the event and all participants with MPD
in the control group did (best case scenario);
 All participants with MPD in the treatment group
had the event and none of participants with MPD in
the control group did (worst case scenario).
We will also use the more plausible assumptions that
the event incidence among participants with missing
data is equal to or higher than the observed event inci-
dence among followed-up and by a specified ratio (see
Table 2). For this purpose, we define RINotFU/FU as the
relative event incidence among those not followed-up
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We will test assumptions combining a range of plausible
RINotFU/FU values (1, 1.5, 2, 3, and 5) in the two comparison
arms. This will follow the methodology our group used to
conduct a similar project focusing on trials (the LOST-IT
project) [8]. In addition, we will use the assumption that
the incidence for missing participants in both arms is the
same as the one observed in the trial control arm.
Making assumptions implies imputing the outcomes
of participants with missing data. That would increase
the total number of events and result in inappropriate
narrowing the CI of the effect estimate. In order to avoid
such inappropriate narrowing of the CI, we will apply
statistical approaches to take into account the uncertainty
associated with imputing outcomes. One recommended
approach consists of using a “variance inflation factor” to
inflate the standard errors or variances of effect estimates
[12,13].
For each of the assumptions, we will calculate the pro-
portion of systematic reviews for which the “assumption
pooled effect estimate” crosses the boundary of conven-
tional statistical significance.
Discussion
The main objective of this study is to assess in Cochrane
and non-Cochrane systematic reviews the impact of differ-
ent methods of dealing with MPD on pooled effect esti-
mates of dichotomous outcomes, with focus on systematic
reviews reporting statistically significant findings. We will
also compare the number of participants that following our
rules would be counted as having MPD with the number of
participants considered in the systematic review counted as
having MPD.
The strengths of our proposed study include the adop-
tion of systematic and transparent methods, including
specific and explicit eligibility criteria, sensitive search
strategies, and duplicate and independent processes for
study selection, data abstraction, and data interpretation
(e.g., judgment about the “actually used” analytical
methods). Also, we will use standardized and pilot tested
forms supplemented with specific and detailed instruc-
tions. We will explore issues that have not previously
been addressed, particularly in terms of the impact of
MPD on pooled effect estimates. Finally, our group has
extensive experience in completing methodological studies
involving large samples [1,14-18].
The major limitation of our study is the need for re-
viewers’ judgments at different stages of the process
(e.g., judgment about the “actually used” analytical
methods). The specific and detailed instructions pilot
testing, and calibration exercises described previously
should help minimize disagreement.
This study will focus on dichotomous outcome data,
given the methodological and statistical issues varysubstantively for continuous data. Also, it will focus on
systematic reviews with a statistically significant pooled
effect estimate for a patient-important efficacy outcome
because they are the most likely to influence clinical
practice.
We will be assessing how Cochrane and non-Cochrane
systematic reviews compare across the three objectives of
this study. A major reason is that the former reviews tend
to be of higher methodological quality compared to the
latter [19,20]. Indeed, we opted to assess the quality of the
included systematic reviews through using two indicators:
the type of systematic review (Cochrane vs. non-Cochrane)
and the use of the GRADE approach. In a recently con-
ducted methodological survey on MPD in systematic
review, regression analyses identified these two factors,
but not the AMSTAR tool, [11] as statistically significant
predictors of two MPD related variables (i.e., whether the
systematic review judged the risk of bias associated with
MPD and whether the systematic review used complete
case analysis) (unpublished data).
For the third objective of this study, and in addition to
assessing the impact of plausible methods of dealing with
MPD, we will assess the impact of implausible methods.
This is because these implausible methods (e.g., none had
the event, all had the event) are sometimes used in pub-
lished meta-analyses. Also, the worst case scenario could
be used to test the robustness of the results [5].
Understanding which categories of trial participants
the systematic review authors consider as having MPD
and how they deal with MPD in meta-analysis will help in
better defining standards for conducting and reporting
systematic reviews. Assessing the impact of different
methods of dealing with MPD on pooled effect estimates
will help judge the associated risk of bias in systematic
reviews. Our findings will inform recommendations re-
garding what assumptions for MPD should be used to
test the robustness of the meta-analytical results. They
will also help in better defining how to assess risk of
bias associated with MPD at the systematic review level
and provide insight into the frequency with which MPD
compromises trust in statistically significant meta-analytical
results. Finally, the publication of this protocol will contrib-
ute to making the objectives and design of methodological
surveys more transparent [2,8,21-24].
Additional files
Additional file 1: Hierarchy of outcomes relative to patient
importance. The hierarchy of outcomes is used for the selection of
the outcome of interest. Categories I, II, and III include patient-important
outcomes. Category IV includes surrogate outcomes, which are not
considered as patient-important.
Additional file 2: Search strategy. Search strategy for non-Cochrane
reviews, using Ovid MEDLINE (R) In-Process and Other Non-Indexed
Citations and Ovid MEDLINE (R) <1946 to Present>.
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